Akero Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
/ 
Frequently asked questions
To buy Akero Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Akero Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Akero Therapeutics Inc. is AKRO:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Akero Therapeutics Inc. has its primary listing on NASDAQ. You can trade Akero Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Akero Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Akero Therapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Akero Therapeutics Inc..